Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications-Reference-Cited by-同舟云学术

Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications

Published:2008-05-01 Issue:S3 Volume:13 Page:4-10
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Gascón Pere¹

Affiliation:

1. Medical Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain

Abstract

Abstract Certain studies in which erythropoiesis-stimulating agents (ESAs) have been given not with the aim of correcting anemia but to achieve higher target levels of hemoglobin have shown significantly poorer survival among treated patients. However, studies in which ESAs were administered with the aim of reducing the need for RBC transfusions in patients with chemotherapy-associated anemia demonstrate that the use of these agents is not associated with any adverse effect on survival when compared with placebo controls. We can therefore be reassured that using ESAs within the labeled indications will not adversely affect patient outcome.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.13-S3-4

Reference50 articles.

1. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients;Ludwig;Eur J Cancer,2004

2. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial;Littlewood;J Clin Oncol,2001

3. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients;Bohlius;J Natl Cancer Inst,2006

4. Once weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy;Shasha;Cancer,2003

5. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial;Henke;Lancet,2003

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer;Women's Health Issues;2016-09

2. Is it time to integrate patient blood management in ERAS guidelines?;Revista Española de Anestesiología y Reanimación;2015-02

3. Impact of Cancer Supportive Care Pathways Compliance on Emergency Department Visits and Hospitalizations;Journal of Oncology Practice;2014-05

4. Management of severe perioperative bleeding;European Journal of Anaesthesiology;2013-06

5. Erythropoietin or darbepoetin for patients with cancer;Cochrane Database of Systematic Reviews;2012-12-12